Titre:
  • Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the phase III randomized, double-blind ECHO and THRIVE trials
Auteur:Nelson, Mark; Amaya, Gerardo; Clumeck, Nathan; Arns da cunha, Clovis; Jayaweera, Dushyantha; Junod, Patrice; Li, Taisheng; Tebas, Pablo; Stevens, Marita; Buelens, Annemie; Vanveggel, Simon; Boven, Katia; Abusamra, Lorena; Cahn, Pedro; Laplume, Héctor; Cassetti, Isabel; Ceriotto, Mariana; Martins, M.D.; Krolewiecki, Alejandro; Amarilis Lugo, L.; Bolan, Robert; Bush, Larry Marc; Corales, Roberto Baun; Crane, Lawrence Richard; De Vente, J.; Fischl, Margaret A.; Gathe, Joseph; Greenberg, Richard; Henry, Kenneth; Jayaweera, D.; Kumar, Princy Suresh; Lalezari, Jacob; Leider, Jason; Lubelchek, Ronald Jay; Martorell, Claudia; Mounzer, Karam; Cohen, Calvin; Olivet, Hannah; Ortiz, Reinaldo; Rhame, Frank; Roberts, Afsoon; Ruane, Peter; Scribner, Anita; Segal-Maurer, Sorana; Short, William; Sloan, Louis; Wilkin, Timothy; Wohlfeiler, Michael; Yangco, Bienvenido
Informations sur la publication:Journal of antimicrobial chemotherapy, 67, 8, page (2020-2028), dks130
Statut de publication:Publié, 2012-08
Sujet CREF:Pharmacologie
Pathologie maladies infectieuses
Mots-clés:Efavirenz
HBV
HCV
Hepatic safety
Hepatitis
Non-nucleoside reverse transcriptase inhibitors
TMC278
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0305-7453
info:doi/10.1093/jac/dks130
info:scp/84864505008
info:pmid/22532465